You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

Citation Tools

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials completed
791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Song Y, Zhou K, Jin C, et al
791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0791